Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids.

Ambrożak A, Steinebach C, Gardner ER, Beedie SL, Schnakenburg G, Figg WD, Gütschow M.

ChemMedChem. 2016 Dec 6;11(23):2621-2629. doi: 10.1002/cmdc.201600496. Epub 2016 Nov 2.

PMID:
27805767
2.

Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.

Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD.

Mol Cancer Ther. 2015 Oct;14(10):2228-37. doi: 10.1158/1535-7163.MCT-15-0320. Epub 2015 Aug 12.

3.

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.

Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G, Helsabeck C, Steinberg SM, LoPiccolo J, Kawabata S, Gardner ER, Figg WD, Dennis PA.

Oncotarget. 2014 Sep 30;5(18):8161-72.

4.

Preformulation study of NSC-726796.

Guo D, Cain JP, O'Connell S, Gardner ER, Pisle S, Figg WD, Tabibi SE, Yalkowsky SH.

AAPS PharmSciTech. 2012 Jun;13(2):661-73. doi: 10.1208/s12249-012-9784-5. Epub 2012 May 3.

5.

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.

Clin Cancer Res. 2012 Apr 1;18(7):2099-107. doi: 10.1158/1078-0432.CCR-11-2484. Epub 2012 Feb 3.

6.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.

Br J Clin Pharmacol. 2011 Aug;72(2):294-305. doi: 10.1111/j.1365-2125.2011.03963.x.

7.

Impact of ABCB1 allelic variants on QTc interval prolongation.

Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.

Clin Cancer Res. 2011 Feb 15;17(4):937-46. doi: 10.1158/1078-0432.CCR-10-0925. Epub 2010 Nov 24.

8.

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.

Clin Cancer Res. 2011 Feb 1;17(3):569-80. doi: 10.1158/1078-0432.CCR-10-1725. Epub 2010 Nov 16.

9.

Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.

Jain L, Gardner ER, Venitz J, Giaccone G, Houk BE, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3187-92. doi: 10.1016/j.jchromb.2010.09.017. Epub 2010 Sep 29.

10.

Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.

Gardner ER, Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD.

Invest New Drugs. 2012 Feb;30(1):90-7. doi: 10.1007/s10637-010-9520-5. Epub 2010 Sep 7.

PMID:
20820910
11.

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE.

Expert Rev Anticancer Ther. 2010 Jul;10(7):997-1008. doi: 10.1586/era.10.88. Review. Erratum in: Expert Rev Anticancer Ther. 2011 Oct;11(10):1622.

PMID:
20645688
12.
13.

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.

Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH.

Pharmacotherapy. 2010 Jan;30(1):52-6. doi: 10.1592/phco.30.1.52.

14.

Pharmacogenetics of membrane transporters: an update on current approaches.

Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD.

Mol Biotechnol. 2010 Feb;44(2):152-67. doi: 10.1007/s12033-009-9220-6. Review.

PMID:
19950006
15.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.

Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27.

16.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.

17.

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL.

Br J Haematol. 2010 Jan;148(2):256-67. doi: 10.1111/j.1365-2141.2009.07954.x. Epub 2009 Oct 28.

18.

Pharmacogenetics of drug transporters.

Franke RM, Gardner ER, Sparreboom A.

Curr Pharm Des. 2010;16(2):220-30. Review.

PMID:
19835554
19.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.

J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13.

20.

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Sissung TM, Thordardottir S, Gardner ER, Figg WD.

Anticancer Agents Med Chem. 2009 Dec;9(10):1058-69. Review.

PMID:
19719457
21.

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.

Gardner ER, Smith NF, Figg WD, Sparreboom A.

J Exp Clin Cancer Res. 2009 Jul 10;28:99. doi: 10.1186/1756-9966-28-99.

22.

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8573-8. doi: 10.1073/pnas.0901505106. Epub 2009 May 11.

23.

A simple, effective and cheap device for the safe irrigation of open traumatic wounds.

Stevens RJ, Gardner ER, Lee SJ.

Emerg Med J. 2009 May;26(5):354-6. doi: 10.1136/emj.2007.055343.

PMID:
19386871
24.

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.

Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215.

25.

Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.

Danish M, Gardner ER, Chen X, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):355-9. doi: 10.1016/j.jchromb.2008.12.018. Epub 2008 Dec 13.

26.

Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.

Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.

BJU Int. 2008 Dec;102(11):1694-9. doi: 10.1111/j.1464-410X.2008.07913.x. Epub 2008 Aug 14.

27.

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.

Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD.

Clin Cancer Res. 2008 Jul 1;14(13):4200-5. doi: 10.1158/1078-0432.CCR-07-4592.

28.

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.

Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A.

Anticancer Drugs. 2008 Mar;19(3):275-81.

29.
30.

Pharmacogenetics of membrane transporters: a review of current approaches.

Sissung TM, Gardner ER, Gao R, Figg WD.

Methods Mol Biol. 2008;448:41-62. doi: 10.1007/978-1-59745-205-2_4. Review.

PMID:
18370230
31.

Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.

Chen X, Gardner ER, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr 1;865(1-2):153-8. doi: 10.1016/j.jchromb.2008.02.015. Epub 2008 Feb 26.

32.

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Jain L, Gardner ER, Venitz J, Dahut W, Figg WD.

J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7.

33.

Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.

Gardner ER, Dahut W, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):213-8. doi: 10.1016/j.jchromb.2007.12.013. Epub 2007 Dec 28.

34.

Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.

Gardner ER, Sparreboom A, Verweij J, Figg WD.

Cancer Biol Ther. 2008 Mar;7(3):412-5. Epub 2007 Dec 13.

PMID:
18094612
35.

Thalidomide analogues as anticancer drugs.

Aragon-Ching JB, Li H, Gardner ER, Figg WD.

Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):167-74. Review.

36.

Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.

Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7.

37.

Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.

Chen X, Gardner ER, Gutierrez M, Kummar S, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):302-6. Epub 2007 Aug 23.

38.

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.

Clin Cancer Res. 2007 Sep 1;13(17):5183-94.

39.

Selective leukemic-cell killing by a novel functional class of thalidomide analogs.

Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W, Ponciano-Jackson D, Chandramouli GV, Gardner ER, Figg WD, Abu-Asab M, Tsokos M, Jackson SH, Gardner K.

Blood. 2006 Dec 15;108(13):4126-35. Epub 2006 Aug 29.

40.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.

Clin Pharmacol Ther. 2006 Aug;80(2):192-201.

PMID:
16890580
41.

Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.

Gardner ER, Liau CT, Chu ZE, Figg WD, Sparreboom A.

Rapid Commun Mass Spectrom. 2006;20(14):2170-4.

PMID:
16779869
42.

Congenital funnel anus: investigation and novel management strategy.

Mahomed AA, Driver CP, Nanthakumaran S, Gardner ER, Youngson GG.

J Pediatr Surg. 2004 Jul;39(7):1119-21.

PMID:
15213912
43.

A painful and deformed wrist.

David-West KS, Gardner ER.

Postgrad Med J. 2002 Mar;78(917):183, 186-7. Review. No abstract available.

44.

Influence of trunk flexion on biomechanics of wheelchair propulsion.

Rodgers MM, Keyser RE, Gardner ER, Russell PJ, Gorman PH.

J Rehabil Res Dev. 2000 May-Jun;37(3):283-95. No abstract available.

PMID:
10917260
45.

Oxygen uptake during peak graded exercise and single-stage fatigue tests of wheelchair propulsion in manual wheelchair users and the able-bodied.

Keyser RE, Rodgers MM, Gardner ER, Russell PJ.

Arch Phys Med Rehabil. 1999 Oct;80(10):1288-92.

PMID:
10527089
47.

Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties.

James PJ, Butcher IA, Gardner ER, Hamblen DL.

J Bone Joint Surg Br. 1994 Sep;76(5):725-7.

PMID:
8083259
48.

Standing balance training: effect on balance and locomotion in hemiparetic adults.

Winstein CJ, Gardner ER, McNeal DR, Barto PS, Nicholson DE.

Arch Phys Med Rehabil. 1989 Oct;70(10):755-62.

PMID:
2802955
49.

Companions in suffering.

Stickney SK, Gardner ER.

Am J Nurs. 1984 Dec;84(12):1491-3. No abstract available.

PMID:
6568796
50.

Psychiatric manifestations of Hashimoto's thyroiditis.

Hall RC, Popkin MK, DeVaul R, Hall AK, Gardner ER, Beresford TP.

Psychosomatics. 1982 Apr;23(4):337-42. No abstract available.

PMID:
6896238

Supplemental Content

Loading ...
Support Center